A Phase 1 interventional study of Ixabepilone and Capecitabine in Breast Cancer, sponsored by R-Pharm. Completed at 4 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-03-10.
Sponsored by R-Pharm · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing ixabepilone in Breast Neoplasms — none open to participants now, 1 under way, none of them phase 3. ixabepilone · Breast Neoplasms.
Among the 41 studies testing ixabepilone in Breast Neoplasms, this one is the 36th largest by enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2008, is one of 7 in phase 1, and was the 15th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 41 studies testing ixabepilone in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
ixabepilone: first FDA approval 2007 (IXEMPRA KIT). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 20 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 29 · Phase 3 5
First in 2000; this study’s year is marked. 11 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 56 across the 39 interventional studies. Of the 38 that completed or were terminated, 28 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 41 have an industry lead sponsor. The 10 most frequent:
R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
15 studies in Breast Neoplasms by R-Pharm: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 15 studies in Breast Neoplasms by R-Pharm, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is one of 6 that started in 2008, is one of 4 in phase 1, and was the 9th registered.
R-Pharm’s Breast Neoplasms studies by the year they started, since 2002.
1 of the studies testing ixabepilone in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00877500M.D. Anderson Cancer CenterIxabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies testing ixabepilone in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among R-Pharm’s 15 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase II dose of ixabepilone in combination with capecitabine in Japanese participants with metastatic breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ixabepilone · Drug: Capecitabine
Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m\^2, once every 3 weeks, up to 6 cycles
Also known as: IXEMPRA, BMS-247550
Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles
Participants Experiencing Dose Limiting Toxicity (DLT)
DLT was defined as any ixabepilone and/or capecitabine related events requiring study discontinuation during the first two treatment cycles.
Time frame: From initiation of drug through last day of Cycle 2 (Day 42)
Participants Achieving the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
The MTD was defined as the highest dose evaluated for which less than 1/3 of the participants experienced DLT during the first two treatment cycles. If toxicities (e.g. hand-foot syndrome, existing peripheral neuropathy, etc.) occurred or became more severe in later cycles, the recommended Phase II dose was to be determined after due consideration of their severity.
Time frame: At the end of Cycle 2 (Day 42)
Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE = any new untoward medical occurrence/worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE = any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related=Possible, Probable, or Certain relationship to drug
Time frame: Baseline to Day 42, continuously
Participant Tumor Response at Study Endpoint
Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) in which complete response (CR) = disappearance of all target lesions; partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; and stable disease (SD) = small changes that do not meet above criteria.
Time frame: At baseline and after every 42 days (every 2 21-day cycles) after baseline
Mean Ixabepilone Maximum Plasma Concentration (Cmax) in One Dosing Interval
Cmax = maximum observed plasma concentration of ixabepilone as determined from participant serum samples in one dosing interval.
Time frame: During Cycle 1 at specified timepoints (Day 1 to Day 8).
Mean Ixabepilone Area Under the Concentration Curve (AUC INF) in One Dosing Interval
AUC = the average area under the concentration curve (AUC \[INF\]) of ixabepilone as determined from participant serum samples in one dosing interval over 24 hours.
Time frame: During Cycle 1 at specified timepoints (Day 1 to Day 8).
Mean Ixabepilone Terminal Elimination Half Life (T 1/2) in One Dosing Interval
T 1/2 = terminal elimination half life as determined from participant serum samples in one dosing interval.
Time frame: During Cycle 1 at specified timepoints (Day 1 to Day 8).
Mean Ixabepilone Volume of Distribution at Steady State (Vss) in One Dosing Interval
Vss = volume of distribution at steady state determined from participant serum samples from one dosing interval.
Time frame: During Cycle 1 at specified timepoints (Day 1 to Day 8).
Mean Ixabepilone Total Body Clearance (CLT) in One Dosing Interval
CLT = total body clearance as determined from participant serum samples in one dosing interval.
Time frame: During Cycle 1 at specified timepoints (Day 1 to Day 8).
Participants were recruited from 4 sites in Japan.
| Milestone | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| Started | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 |
DLT was defined as any ixabepilone and/or capecitabine related events requiring study discontinuation during the first two treatment cycles.
| Participants | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| Participants Experiencing Dose Limiting Toxicity (DLT) | 0 | 0 | 0 |
AE = any new untoward medical occurrence/worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE = any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related=Possible, Probable, or Certain relationship to drug
| Participants | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| AEs | 3 | 3 | 3 |
| Related AEs | 3 | 3 | 3 |
| Discontinued Due to AEs | 0 | 0 | 0 |
| SAEs | 0 | 1 | 1 |
| Related SAEs | 0 | 1 | 1 |
| Discontinued Due to SAEs | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 |
Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) in which complete response (CR) = disappearance of all target lesions; partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; and stable disease (SD) = small changes that do not meet above criteria.
| Participants | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| CR | 0 | 0 | 1 |
| PR | 1 | 1 | 2 |
| PD | 1 | 1 | 0 |
| SD | 1 | 1 | 0 |
Cmax = maximum observed plasma concentration of ixabepilone as determined from participant serum samples in one dosing interval.
| ng/mL | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| Mean Ixabepilone Maximum Plasma Concentration (Cmax) in One Dosing Interval | 164.01 ± 30 | 219.44 ± 13 | 192.13 ± 6 |
AUC = the average area under the concentration curve (AUC \[INF\]) of ixabepilone as determined from participant serum samples in one dosing interval over 24 hours.
| ng·h/mL | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| Mean Ixabepilone Area Under the Concentration Curve (AUC INF) in One Dosing Interval | 1260.71 ± 1 | 1676.46 ± 24 | 1417.78 ± 10 |
T 1/2 = terminal elimination half life as determined from participant serum samples in one dosing interval.
| Hours | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| Mean Ixabepilone Terminal Elimination Half Life (T 1/2) in One Dosing Interval | 41.77 ± 9 | 44.17 ± 8 | 54.27 ± 16 |
Vss = volume of distribution at steady state determined from participant serum samples from one dosing interval.
| Liters | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| Mean Ixabepilone Volume of Distribution at Steady State (Vss) in One Dosing Interval | 1910.13 ± 423 | 1498.46 ± 140 | 2055.55 ± 795 |
CLT = total body clearance as determined from participant serum samples in one dosing interval.
| L/h | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| Mean Ixabepilone Total Body Clearance (CLT) in One Dosing Interval | 41.52 ± 2 | 37.21 ± 7 | 42.79 ± 7 |
The MTD was defined as the highest dose evaluated for which less than 1/3 of the participants experienced DLT during the first two treatment cycles. If toxicities (e.g. hand-foot syndrome, existing peripheral neuropathy, etc.) occurred or became more severe in later cycles, the recommended Phase II dose was to be determined after due consideration of their severity.
| Participants | All Participants With Measurable Disease and Tumor Response |
|---|---|
| Ixa 40 mg/m^2 + Cap 2000 mg/m^2 MTD | 3 |
| Ixa 40 mg/m^2 + Cap 2000 ng/m^2 RP2D | 3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | — | 0/3 (0%) | 3/3 (100%) |
| Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | — | 1/3 (33.3%) | 3/3 (100%) |
| Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day | — | 1/3 (33.3%) | 3/3 (100%) |
| Event | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| SKIN INFECTIONInfections and infestations | 0/3 | 1/3 | 0/3 |
| NEUTROPENIABlood and lymphatic system disorders | 0/3 | 0/3 | 1/3 |
| Event | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day |
|---|---|---|---|
| HAEMOGLOBIN DECREASEDInvestigations | 1/3 | 2/3 | 3/3 |
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 3/3 | 3/3 | 3/3 |
| NAUSEAGastrointestinal disorders | 1/3 | 3/3 | 2/3 |
| DECREASED APPETITEMetabolism and nutrition disorders | 2/3 | 3/3 | 3/3 |
| LEUKOPENIABlood and lymphatic system disorders | 3/3 | 3/3 | 3/3 |
| NEUTROPENIABlood and lymphatic system disorders | 3/3 | 3/3 | 3/3 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 0/3 | 3/3 | 3/3 |
| PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders | 2/3 | 0/3 | 3/3 |
| MYALGIAMusculoskeletal and connective tissue disorders | 3/3 | 3/3 | 2/3 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 2/3 | 3/3 | 3/3 |
| Age, Categorical(Participants) | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 2 | 8 |
| >=65 years | 0 | 0 | 1 | 1 |
| Age, Continuous(years) | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day | Total |
|---|---|---|---|---|
| Mean | 54.0 ± 13.00 | 52.7 ± 4.73 | 52.7 ± 20.26 | 53.1 ± 12.28 |
| Sex: Female, Male(Participants) | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day | Total |
|---|---|---|---|---|
| Female | 3 | 3 | 3 | 9 |
| Male | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day | Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day | Total |
|---|---|---|---|---|
| Japan | 3 | 3 | 3 | 9 |
The record gives a start of Feb 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ixabepilone · Capecitabine